Close Menu

skin cancer

Verisante Technology said this week it has signed an exclusive distribution deal with Pacifica Handels to distribute its Aura skin cancer detection device in Switzerland.

Verisante Technology said this week that it has received the first orders for its Raman spectroscopy-based Aura skin cancer detection system and plans an initial production run of 10 devices to be placed in Canada and Europe.

Researchers from the British Columbia Cancer Agency this week presented results from a clinical study in which Verisante Technology's Raman spectroscopy-based Core device distinguished between cancerous and benign lung lesions with sensitivity and specificity of more than 90 perc

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

In addition to a five-marker diagnostic test that the company plans to launch in the second half of 2011, Myriad is developing a second melanoma test that would gauge survival benefit.

GSK is conducting a Phase III study for a MAGE-A3-targeting therapeutic for the adjuvant treatment of melanoma. To receive the drug in the study, participants' tumors must be shown to express MAGE-A3 via a molecular test that Abbott is developing.

Abbott and GSK will develop and commercialize a PCR test for the MAGE-A3 biomarker using Abbott's m2000 automated real-time PCR system.

Pages

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.